Wear particle-induced peri-implant loosening is the most common complication affecting long-term outcomes in patients who undergo total joint arthroplasty. Wear particles and by-products from joint replacements may cause chronic local inflammation and foreign body reactions, which can in turn lead to osteolysis. Thus, inhibiting the formation and activity of osteoclasts may improve the functionality and long-term success of total joint arthroplasty. The aim of this study was to interfere with CXC chemokine receptor type 2 (CXCR2) to explore its role in wear particle-induced osteolysis.
Background
Total joint arthroplasty (TJA) is the criterion standard treatment for end-stage joint diseases to relieve pain and restore function. Although extensive efforts have been made to improve the quality and efficacy of TJA, wear particle-induced osteolysis and subsequent aseptic loosening (AL) remain the most common factors that limit the long-term success of arthroplasty surgery and lead to the need for revision surgery. The crucial factor contributing to AL is an adverse tissue response to wear particles that are generated at the surface of the prosthesis, which results in bone loss and promotes osteoclast formation at the site of the bone implant [1, 2] .
Previous studies revealed that the central event during particleinduced osteolysis is osteoclast formation, which is modulated by the monocytes/macrophages and osteoblasts. Osteoclasts are derived from monocyte/macrophage precursors when nuclear factor-kB ligand (RANKL) is overexpressed. RANKL signaling plays an important role in the activation of osteoclasts. Osteoprotegerin (OPG) can inhibit RANKL signaling because it is a decoy receptor secreted by osteoblasts. Therefore, osteoblasts play a part in osteolysis by regulating RANKL and OPG production. Indeed, macrophages produce growth factors (e.g., M-CSF, GM-CSF, and VEGF), inflammatory factors (e.g., TNF-a, IL-1b, IL-6, and PGE2) and chemotactic factors (e.g., IL-8, CCL3, and CCL2) in response to prosthesis material, all of which induce receptor activation and RANKL expression to stimulate bone destruction. Recently, IL-8 and its receptors have become popular therapeutic agents for wear particle-induced osteolysis; these chemotactic cytokines also mediate osteoclastogenesis [3, 4] .
IL-8, also known as CXCL8, is a member of the CXC chemokine family and is the primary cytokine secreted by macrophagocytes. It is strongly expressed in primary human breast cancers, and its expression is strongly correlated with elevated bone resorption in breast cancer patients [5] . IL-8 induces RANKL expression in stromal osteoblastic cells and promotes the differentiation of human peripheral blood mononuclear cells into bone-resorbing osteoclasts in a manner that is independent of RANKL [6] . Human osteoclasts express high levels of IL-8, which promotes osteoblast-mediated osteoclast maturation. The coupled receptors for IL-8 are CXC-chemokine receptor type 1 (CXCR1) and type 2 (CXCR2), which are located on the surface of macrophages, epithelial cells, mast cells, and endothelial cells [7] . CXCR2 is a potent neutrophil chemoattractant that regulates neutrophil homeostasis and recruitment, and is released from bone marrow as a response to injury and acute inflammation [8, 9] . The IL-8/CXCR2 signaling pathway is upregulated in many cancers, including pancreatic, prostate, renal, and nasopharyngeal cancer [10, 11] . The role of IL8/CXCR2 signaling in particle-induced osteolysis appears to be mostly detrimental, since CXCR2 was associated with osteoclast differentiation, bone resorption, and the promotion of aseptic-loosening. Furthermore, CXCR2-deficient mice exhibited suppressed neutrophil recruitment and decreased tissue injury [12, 13] . However, it remains unclear whether IL-8 plays a role in osteoclastogenesis via CXCR2 or pathological osteolysis.
The objective of the current study was to investigate the effects of IL8/CXCR2 signaling on wear particle-induced osteolysis. We hypothesized that silencing CXCR2 might attenuate osteoclast formation.
Material and methods

Reagents
Soluble recombinant mouse RANKL was obtained from Prospec Systems (East Brunswick, NJ). Anti-TRAP and -CXCR2 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and RANKL, TRAP, CtsK, NFATc1, and OPG antibodies were purchased from Cell Signaling Technology (Beverly, MA). Alpha-minimum essential medium (a-MEM) was purchased from Hyclone (Logan, UT). Fetal bovine serum (FBS) was obtained from Gibco (Carlsbad, CA).
Cell culture
For primary cultures, bone marrow-derived macrophages (BMMs) were obtained from BALB/c mice (4-6 weeks old). Cells were cultured in a-MEM supplemented with 10% FBS and 1% penicillin/streptomycin for 24 h. Floating cells were removed, and the adherent cells were cultured in 5% CO 2 at 37°C for 12 h. They were then treated with adenovirus-mediated CXCR2 or MS siRNA, macrophage colony-stimulating factor (M-CSF), and RANKL, and the culture media were replaced every 2 days until mature osteoclasts had formed. Primary mouse osteoblasts were acquired from female BALB/c mice calvaria using standard methods. 
Ti-particle-induced calvarial osteolysis model
A mouse calvarial osteolysis model was established to measure the osteolysis-suppressing effects of siCXCR2 in vivo. We purchased 4-6-week-old female BALB/c mice weighing ~30 g from the Animal Experiment Center of Chongqing Medical University. Mice received local calvaria injections of 100 µl Ti particles and were then randomly divided into 3 study groups that received injections of adenovirus expressing CXCR2 siRNA (CXCR2 group), missense siRNA (MS group), or virus-free culture medium (control group). Two mice died, but no adverse reactions were observed during the experiment. The mice were sacrificed by ether inhalation after 3 weeks and the calvaria were excised and fixed in 4% paraformaldehyde for TRAP, hematoxylin and eosin (H&E) staining, and micro-CT.
Tartrate-resistant acid phosphatase (TRAP) staining
Cells were fixed with 4% paraformaldehyde, washed with distilled water, and stained for TRAP in a humid and light-protected incubator for 1 h using the Leukocyte Acid Phosphatase Assay kit (Sigma). TRAP-positive cells containing 2 or more nuclei were regarded as osteoclasts.
A microscope (80i Eclipse, Nikon, Japan) was used to capture images of TRAP-stained pouch sections and observe TRAPpositive osteoclast-like cells (400× magnification). Due to the blurred boundaries of TRAP-positive cells stained dark red in the calvaria sections, analysis software (Image-Pro Plus 6.0) was used to quantify the number of TRAP-positive osteoclast-like cells on the bone-membrane interface by comparing the dark red colored area with the total implanted bone area (400× magnification).
Bone resorption pit assay
Bone slices were treated with RANKL (50 ng/ml) and M-CSF (30 ng/ml) and then incubated with adenovirus-mediated CXCR2 siRNA or MS siRNA. Bone slice images were captured using a scanning electron microscope (SEM Hitachi S-4800, CamScan, Tokyo, Japan) at 10 kV. Three fields of each bone slice were randomly selected and the pit areas were quantified using Image J software.
Micro-CT
Calvariae were analyzed using high-resolution micro-CT (Skyscan1072, Skyscan, Aartselaar, Belgium) with an isometric resolution of 9 mm and X-ray energy settings of 80 kV and 80 mA. A 2×2 mm square region of interest (ROI) with the midline suture was selected for further quantitative and qualitative testing after reconstruction. The number of pores, body volume/tissue volume (BV/TV), and bone mineral density (BMD) in the ROI were measured.
Western blotting
Protein lysates were generated from the cell cultures using standard techniques. The protein concentrations were determined using bicinchoninic acid (BCA), and lysates were separated using 8-12% SDS-PAGE gel electrophoresis and electrotransferred to PVDF membranes. The membranes were blocked with 5% non-fat milk and then probed with primary antibodies followed by peroxidase-labelled secondary antibodies. Finally, the protein bands were visualized using enhanced chemiluminescence (ECL, KeyGen, Nanjing, China).
Real-time PCR
Total RNA was extracted from cells using Trizol reagent (Invitrogen) and reverse transcribed into single-stranded cDNA using BioTeke Super RT kit (Bioteke Corp., Beijing, China) according to the manufacturer's instructions. The target genes were PCR amplified using a LightCycler™ 96 Real-time PCR system (Roche, Nutley, NJ, USA) and normalized to GAPDH as the internal control. The sample-cycling conditions were as follows: 95°C for 60 s, 40 cycles of 95°C for 10 s, 60°C for 30 s, 72°C for 30 s, and 60°C for 30 s. The sequences of the primers were: CtsK forward, 5'-CTTCCAATACGTGCAGCAGA-3' and reverse, 5'-TCTTCAGGGCTTTCTCGTTC-3'; TRAP forward, 5'-CTGGAGTGCACGATGCCAGCGACA-3' and reverse, 5'-TCCGTGC TCGGCGATGGACCAGA-3'; RANKL forward, 5'-AGAAGGACG GGACATCGC-3' and reverse, 5'-AGGTGGTAGGAGGCAGAGG-3'; and c-Fos forward, 5'-CCAGTCAAGAGCATCAGCAA-3' and reverse, 5'-AAGTAGTGCAGCCCGGAGTA-3' (Metabion; Martinsried, Germany).
Statistical analysis
Statistical analyses were performed using ANOVA with SPSS. Data are expressed as means ± standard deviations (SDs) from at least 3 independent experiments. * P<0.05 or ** P<0.01 were considered to indicate statistical significance.
Results
CXCR2 is upregulated during RANKL-induced osteoclastogenesis in RAW264.7 cells
To determine CXCR2 expression during osteoclastogenesis, RAW264.7 cells were treated with or without RANKL for 7 days. 
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Flow cytometry revealed that RANKL treatment increased the expression of cell-surface CXCR2 ( Figure 1A ). Western blotting demonstrated that CXCR2 levels were higher in whole-cell extracts ( Figure 1B) . Therefore, CXCR2 might play an important role in osteoclast formation.
CXCR2 inhibition by siRNA in vitro
CXCR2 expression in primary osteoclasts was inhibited using siRNA. Bone marrow mononuclear cells were treated with adenovirus-mediated MS or CXCR2 siRNA and then cultured in the presence of RANKL and M-CSF. Western blotting (Figure 2) showed that CXCR2 levels were significantly downregulated in the CXCR2 group compared with the control and MS groups. Treatment with siRNA suppressed CXCR2 protein levels by ~70%. This suggests that adenovirus-mediated CXCR2 siRNA is a highly efficient inhibitor of CXCR2 expression.
CXCR2 siRNA inhibits titanium particle-induced osteolysis in vivo
The effects of siCXCR2 on pathological osteolysis were determined using a Ti-particle-induced calvarial osteolysis model in vivo. The MS and control groups showed significant calvarial This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License osteolysis compared with the CXCR2 group. Bone erosion was reduced when siCXCR2 was injected together with the Ti particles ( Figure 3A) . Quantitative analysis confirmed that siCX-CR2 injection increased the BV/TV and BMD ( Figure 3B, 3C) and also lowered the bone porosity compared with the MS and control groups in the calvaria ( Figure 3D ).
Histological analysis confirmed that siCXCR2 attenuated Ti particle-induced osteolytic bone loss ( Figure 3E ). TRAP-positive osteoclasts accumulated along the eroded bone surface in the MS and control groups, but there were fewer osteoclasts and the osteolysis surface area was reduced in the siCXCR2 group ( Figure 3F, 3G) . These data were consistent with the micro-CT results, revealing that local injection with siCXCR2 can effectively treat Ti particle-induced osteolysis.
CXCR2 signaling in osteoclastogenesis in vitro
Our previous observations suggested that siCXCR2 attenuated titanium particle-induced osteoclastogenesis. However, the This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License mechanism of action of CXCR2 on osteoclastogenesis in osteoblasts remains unclear. Therefore, we explored the role of the CXCR2 signaling pathway in osteoclastogenesis in vitro. We first examined the effects of adenovirus-mediated CXCR2 siRNA on osteoclast formation. The number of TRAP-positive osteoclasts in the presence of RANKL decreased after treatment with adenovirus-mediated CXCR2 siRNA ( Figure 4A-4C ). In addition, our previous study suggested that osteoclast resorption could also be inhibited by siCXCR2. Here, the area of resorption was reduced in the CXCR2 group compared with the MS and control groups ( Figure 4D, 4E) .
Next, real time-PCR was to measure and quantify the expression of osteoclast-related genes, including RANK, TRAP, cathepsin-K (CtsK), and c-Fos (Figure 5A ), in cells transfected with adenovirus-mediated CXCR2 siRNA. We then used Western blotting to measure the protein expression of the osteoclast markers TRAP and CtsK after 7 days ( Figure 5B ). The expression of RANK, TRAP, CtsK, and c-Fos mRNA was markedly reduced in the CXCR2 group compared with the MS and control groups. The Western blotting results were similar ( Figure 5A , 5B). 
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To explore further the role of CXCR2 signaling in osteoclast formation we investigated the effects of siCXCR2 on the RANKL-induced expression of Nuclear Factor of Active T cell c1 (NFATc1), a critical regulator of osteoclast formation, using Western blotting. As shown in Figure 5B , siCXCR2 decreased NFATc1 levels in the presence of RANKL and MCSF, suggesting that CXCR2 signaling affects osteoclast formation by downregulating NFATc1 expression.
RANKL and OPG are secreted by osteoblasts and expressed on the surface of osteoblasts, and they promote and inhibit osteoclast formation and function, respectively. Therefore, the expression of OPG and RANKL was measured after treatment with siCXCR2 in primary osteoblasts. Figure 6 shows that siCX-CR2 significantly increased OPG and reduced RANKL protein expression in osteoblasts.
The current results demonstrate that silencing CXCR2 signaling directly inhibits osteoclast formation, and acts on osteoblasts indirectly to suppress osteoclast differentiation by altering OPG and RANKL expression.
Discussion
Total joint arthroplasty is a surgical intervention for the treatment of severe joint disease and trauma. However, aseptic loosening of artificial joints resulting in periprosthetic osteolysis remains the main cause of failure in artificial joint replacement, and frequently results in the need for further surgery [3, 14] .
The results of the current study demonstrate that CXCR2 expression is upregulated during osteoclast formation, which suggests that CXCR2 may play a vital role in osteolysis. CXCR2 is a receptor for IL-8, and is found on the surface of macrophages, epithelial cells, osteoclasts, and osteoblasts [7] . It participates in the pathological processes involved in chronic inflammation, osteolysis, and atherosclerosis [15] [16] [17] . Although the CXC chemokine family plays a vital role in recruiting osteoclasts as autocrine or paracrine moderators, few studies have linked CXCR2 signaling with osteoclast formation in titanium-induced osteoclast formation. Taken together, these data suggest that siCXCR2 reduced the bone resorption rates in a mouse calvarial model in the current study by suppressing osteoclastogenesis. 
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Osteoclasts play a critical role in the wear particle-induced bone resorption area, and therefore are an efficient and viable treatment target [18, 19] . CXCR2 signaling is upregulated around periprosthetic tissues [20] , and different wear particles (such as titanium) increase CXCR2 expression in macrophages and MSCs in localized periprosthetic tissues [21] . This can then induce osteoclast and macrophage migration to areas around implants, which accelerates osteolysis [22] . The current study revealed that there were fewer TRAP-positive cells in the siCXCR2 group compared with the MS and control groups, which suggests that siCXCR2 can inhibit osteoclastogenesis. The resulting inhibition of osteoclast differentiation and maturation resulted in dramatically reduced bone resorption pits and resorption area after treatment with siCX-CR2. Furthermore, siCXCR2 also suppressed osteoclast-related gene expression. Taken together, these data suggest that the protective effects of siCXCR2 on Ti particle-induced osteolysis are modulated directly by its inhibitory effects on osteoclasts. Overall, the current findings demonstrate that Ti particle-induced osteolysis can be effectively suppressed by inhibiting CXCR2 signaling.
The dynamic balance between RANKL and OPG is crucial during the regulation of bone formation and resorption because it regulates osteoclast activation [23] . RANKL promotes osteoclast formation and differentiation, whereas OPG inhibits bone resorption. Furthermore, recent studies suggested that the balance between RANKL and OPG plays an important role in particle-induced osteolysis [24, 25] . In the current study, siCXCR2-treated cells exhibited downregulated RANKL and upregulated OPG protein expression in primary osteoblasts. This suggests that siCXCR2 works on osteoblasts indirectly to suppress osteoclast differentiation by altering the balance between RANKL and OPG, which is consistent with previous findings [26] . Although the underlying pathogenesis of aseptic loosening is a complex process, the current results suggest that IL-8/CXCR2 signaling plays a role in osteoclast formation and titanium particle-induced osteolysis. Therefore, CXCR2 and its ligands are potential therapeutic targets to remedy aseptic loosening.
Conclusions
There is a growing need for more targeted approaches to the treatment and early diagnosis of harmful debris-induced inflammation [27] . Locally injected adenovirus-mediated CXCR2 siRNA could be an effective approach to treat titanium particle-induced osteolysis.
